Doxorubicin-induced cardiomyopathy treated with carvedilol

Clinical Cardiology

Volumn 21, Issue 10, 1998, Pages 777-779

  Fazio, Serafino ^a   Palmieri, Emiliano Antonto ^a   Ferravante, Beatrice ^a   Bone, Filomena ^a   Biondi, Bernadette ^a   Saccà, Luigi ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Cardiomyopathy; Carvedilol; Doxorubicin

Indexed keywords

CARVEDILOL; CYCLOPHOSPHAMIDE; DIGOXIN; DOXORUBICIN; ENALAPRIL; FLUOROURACIL; FUROSEMIDE; METHOTREXATE;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CARDIOMYOPATHY; CASE REPORT; CLINICAL FEATURE; DRUG INDUCED DISEASE; DYSPNEA; EDEMA; FEMALE; HUMAN; INTRADUCTAL CARCINOMA; MASTECTOMY;

EID: 0031709555     PISSN: 01609289     EISSN: None     Source Type: Journal    
DOI: 10.1002/clc.4960211017     Document Type: Article

References (9)

1. Young RC, Ozol RF, Myers CE: The anthracycline antineoplastic drugs. NEngUMcd 1981; 305:139-153
2. van Hoff DD, Layard MW, Basa P, Davis HL Jr, von Hoff AL, Rozencweig M, Muggia FM: Risk factors fordoxorubicin-induced congestive heart failure. Ami Intern Med 1979;91:710-717
3. Choen M, Kronzon I, Lebowitz A: Reversible doxorubicin-induced congestive heart failure. Arch Intern Mec! 1982; 142:1570-1571
4. Saini J, Rieh MW, Lyss AP: Reversibility of severe left ventricular dysfunction due to doxorubicin cardiotoxicity. Report of three cases. Ann Intern Med 1987; 106:814-816
5. Gianni L, Corden BJ, Myers CE: The biochemical of anthracycline toxicity and anti tumoral activity. In Reviews in Biochemical Toxicology (Eds. Hodgson E, Bend JR, Philport RM), p. 1-82. Amsterdam: Elsevier, 1983
6. Doroshow JH: Effect of anthracycline antibiotics on oxygen radical formation in rat heart. Cancer Res 1983;43:460-472
7. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH: The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. NEngl J Med 1996;334:1349-1355
8. Yue TL, Cheng HY, Lysko PG, McKenna PJ, Feuerstein R, Gu JL, Lysko KA, Davis LL, Feuerstein G: Carvedilol, a new vasodilator and beta adrenoceptor antagonist, is an antioxidant and free radical scavenger. J Pliarmacol Exp Thcr 1992;263:92-98
9. Bril A, Slivjak M, Di Martino MI, Feuerstein GZ, Linee P, Poyser RH, Ruffolo RR Jr, Smith EF: Cardioprotective effects of carvedilol, a novel beta adrenoceptor antagonist with vasodilating properties, in anaesthetized minipigs: Comparison with propranolol. CardiovascRcs 1992;26:518-525